For over a century, a lot of efforts were invested in developing strategies to target IGF1 receptor (IGF1R) in cancer therapy, but accumulating data from clinical study indicated that specific targeting of the IGF1R was not efficient as an anti‐breast cancer therapy 36. This evidence concerns the gene IGF1R and breast carcinoma.